Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06106035 · ClinicalTrials.gov registry record · NA
The Effect of a Low-fat Vegan Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes
A NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus Type 2 in Obese, sponsored by Physicians Committee for Responsible Medicine.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT06106035: Completed NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus Type 2 in Obese, sponsored by Physicians Committee for Responsible Medicine.
NCT06106035 is a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus Type 2 in Obese that has completed, run by Physicians Committee for Responsible Medicine. The registered enrollment target is 26 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06106035, a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus Type 2 in Obese, has completed, sponsored by Physicians Committee for Responsible Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this 16-week clinical trial is to assess the health benefits of a low-fat vegan diet on insulin sensitivity and glycemic control in type 2 diabetes. Participants will receive at no cost, study-related weekly nutrition education classes and one-on-one consultation with a registered dietitian.
Primary Outcome
MR spectroscopy will be used to quantify liver and muscle fat content. This study will assess the association of attending a series of plant-based nutrition classes with pre-post changes in intramyocellular and hepatocellular lipid content.
Conditions Studied
Interventions
- BEHAVIORAL low-fat vegan diet
Study Locations (1)
District of Columbia
- Physicians Committee for Responsible Medicine - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-02-13 |
| Est. Completion | 2025-11-28 |
| Phase | NA |
What the finished NCT06106035 record still lists
NCT06106035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which low-fat vegan diet is the first listed.
NCT06106035 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06106035 about?
NCT06106035 is a clinical study titled "The Effect of a Low-fat Vegan Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes". The goal of this 16-week clinical trial is to assess the health benefits of a low-fat vegan diet on insulin sensitivity and glycemic control in type 2 diabetes. Participants will receive at no cost, study-related weekly nutrition education classes and one-on-one consultation with a registered dietit...
What is the current status of trial NCT06106035?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2024-02-13. Estimated completion is 2025-11-28.
What conditions does trial NCT06106035 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 in Obese.
What interventions are being tested in trial NCT06106035?
The interventions under investigation include: low-fat vegan diet (BEHAVIORAL).
Who is sponsoring clinical trial NCT06106035?
This trial is sponsored by Physicians Committee for Responsible Medicine, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06106035 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06106035's enrollment target sits among peer trials
26 306th of 348 higher than 42 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI